{'fraction_non_alphanumeric': 0.01977401129943503, 'fraction_numerical': 0.00847457627118644, 'mean_word_length': 4.71505376344086, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Letters to the Editor

Dr. Miller disputes the prevalence figure of 16% which we reported in our study. Our finding lies in the mid-range of prevalence rates in studies which have identified sweating as a specific problem. Other studies, such as that by Donnelly and Walsh (1), which have documented the prevalence of a wide variety of symptoms in patients with advanced cancer, have not reported on the frequency of sweating. The difference between our positive reporting and those studies which have not identified sweating as a problem does not, however, diminish the importance of sweating as a troublesome symptom in patients with advanced cancer. The 16 patients in our study who complained of sweating spontaneously volunteered it as a problem. Positive probing did not reveal further cases in the other 84 patients. This supports our figure of 16% as a reflection of the true prevalence of sweating in the group of patients whom we studied. We agree with Dr. Miller about the importance of prospective studies, hence the prospective design of our survey.